TNFRSF8 negative

Overall, EPOCH was well tolerated with high response rates in first line and R/R setting.

These entities are currently treated similarly with CHOP or CHOEP for CD30-negative diseases or brentuximab vedotin plus CHP for CD30-positive diseases, followed by consolidation with autologous stem cell transplant in first remission...Although current treatment strategies lump most disease entities together, future treatment will include distinct strategies for each disease subtype that optimizes therapy for individuals. This movement towards individualized therapy will ultimately lead to dramatic improvements in prognosis for patients with PTCL.

P1, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center

Following discussions with Henry Ford Lymphoma Tumor Board, patient was treated with six cycles of R-CHOP, where follow-up imaging indicated remission of her lymphoma. ConclusionThis represents an extraordinary first report of HGBL NOS manifesting as an isolated primary hepatic lymphoma in the complete absence of clinical symptoms. The significance of this case lies in its atypical extra-nodal site of involvement and total absence of clinical symptoms and serological markers, underscoring the unfulfilled need to further describe this enigmatic entity.

These results indicate that BCL11b may be involved in CD30 differentiation and PTCL prognosis. The detection and targeting of BCL11b and CD30 may provide new strategies for the treatment and classification of PTCL.

No abstract available

We provide a framework for unbiased, multi-dimensional target screening and highlight the functional relevance of the immunosuppressive CTLA-4-CD86 axis in HL. Our results further emphasize the role of anti-CD86 - targeted therapies either as an alternative to or in conjunction with anti-CD30-based therapies in HL.

In CD30-negative ROIs in MF-LCT compared to cALCL, memory B (p=0.021), plasma (p=0.023), and CD8 memory T (p=0.001) cells significantly decreased whereas regulatory T cells (p=0.024) increased. Predomination of ECM remodeling pathways and immunosuppressive microenvironment in MF-LCT indicates pathophysiological differences from MF-LCT and cALCL.

P2, N=58, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025

KEY MESSAGE: The importance of acknowledging the evolution of this pathology is to recognize it in its early stages. Additionally, the peripheral blood flow cytometry categorizes the patient as class B1 or “pre-Sézary syndrome”

LyP treatment options include topical steroids, topical bexarotene, phototherapy, nitrogen mustard, methotrexate, and intralesional interferon. In our patient, the papules and ulcerated plaques regressed under treatment with methotrexate

Since the approval of brentuximab vedotin (BV), assessment of CD30 status by immunohistochemistry gained increasing importance in the clinical management of patients diagnosed with CD30-expressing lymphomas, including classical Hodgkin lymphoma (CHL)...Three CHL cases with weak staining may have been missed without the use of control tissue for low expression. Thus, standardization of CD30 immunohistochemical staining with use of known low-expressing controls may aid in proper CD30 assessment and subsequent therapeutic stratification of patients.

The most adopted therapeutic strategy in children is based on heliotherapy or an antibiotic from the macrolide or cyclin family or UVB phototherapy. PLC is a most often benign dermatitis, evolution towards mycosis fungoides has been rarely describedhence the need for regular follow-up.

The R-CHOP chemoimmunotherapy is the first-line standard treatment regimen for Diffuse Large B-Cell Lymphoma (DLBCL) patients...Recently completed a clinical study of Hodgkin Lymphoma (5) and a pre-clinical study of DLBCL (6) have demonstrated that the toxicity of CD30 antibody-drug conjugate Brentuximab Vedotin (BV) in CD30-negative tumor cells is dependent on CD30-positive exosomes...Similarly, a possible function of CD79B-positive exosomes in the therapeutic efficacy of the anti-CD79B antibody-drug conjugate Polatuzumab Vedotin have not yet determined. Identifying characteristics of tumor cells as well as targeting different supporters contributing to tumor microenvironment will improve the therapeutic strategy of precision medicine.

Background: In ECHELON-2, brentuximab vedotin (BV), a CD30-directed ADC, combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP) enrolled patients (pts) with ALCL and other types of PTCL with ≥10% CD30 expression. Initial findings show that A+CHP is effective for pts with PTCL regardless of CD30 expression by local testing. Safety results are consistent with previous data from ECHELON-2 and no new safety signals were observed. This study is ongoing and updated results will be presented in the future.

This phase 2 study evaluated oral azacitidine (CC-486) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as initial treatment for PTCL. DNA methylation did not show significant shift. This safe and active initial therapy regimen is being further evaluated in the ALLIANCE randomized study A051902 in CD30-negative PTCL.

In order to target HER2, systemic treatment was changed to a combination containing trastuzumab and pertuzumab, resulting in pathological complete response...Staining showed high PDL-1 (CPS50), prompting a change in therapy to an anti-PDL-1 (pembrolizumab) therapy... RNA-seq is emerging as an objective tool to evaluate key diagnostic and targetable events in multiple cancer types. The use of RNA-seq can also add value as an objective measurement to confirm critical IHC findings, potentially changing clinical care.

He started a second cycle of chemotherapy with bleomycin, etoposide, and cisplatin (BEP) per AGCT1532 however, again, had poor response...He received triple intrathecal chemotherapy once followed by treatment per ANHL12P1 with crizotinib, dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide with good response... This case report details the adverse effects on pathological diagnosis from treatment with corticosteroids. This patient’s poor response after multiple lines of chemotherapy may be due to diagnostic uncertainty secondary to emergent corticosteroid treatment prior to his biopsy. Providers should be aware of the potential adverse effects of corticosteroids on biopsy results, which may lead to misdiagnoses, delays in management, and incorrect treatment regiments.

P2, N=58, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024

P1, N=16, Active, not recruiting, Fox Chase Cancer Center | Recruiting --> Active, not recruiting | N=27 --> 16 | Trial completion date: Jul 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023

This case expands understanding of morphologic transformation between different subtypes of ALK + ALCL and highlights common diagnostic pitfalls, including atypical morphology and negative CD30. Morphologic transformation of ALK + ALCL should be assigned importance, and comprehensive clinical history, histologic and immunophenotypic evaluation are vital to rendering the correct diagnosis of ALK + ALCL.

No abstract available

As HRS morphology of neoplastic cells and CD30 expression are frequent features of EBV-positive NLPHL, preservation of the B-cell transcription programme, MEF2B expression combined with NLPHL-typical architecture and background composition facilitate distinction from CHL. EBER ISH is the method of choice to identify these cases. The majority present with EBV latency type II, and only rare cases present with latency type I, which can be associated with missing CD30 expression. The presence of occasional bystander lymphocytes expressing BZLF1 and/or EBNA-2 and the partial EBV infection of neoplastic cells in some cases could indicate that EBV is either not primarily involved or is only a transient driver in the pathogenesis of EBV-positive NLPHL.

For pts 10% by immunohistochemistry, and most significantly improved outcomes in anaplastic large cell lymphoma...The study was activated 7/30/2021 and the safety lead-in portion is currently enrolling. Support: U10CA180821, U10CA180882.

The patient received a course of intravenous methylprednisolone and presented three months later with worsening headaches associated with somnolence...Treatment with methotrexate, procarbazine and vincristine was initiated... Primary CNS T-cell lymphoma is a very rare condition especially in young adults. It is difficult to distinguish it from other conditions clinically, radiologically and histopathologically. Diagnosis requires a high level of suspicion and TCR should be performed when atypical features are present.

To our knowledge, this is the first report describing the correspondence between FCM and immunohistochemistry findings for CD30 through newly proposed notations. The PRIME-F and PRIME-I notations for CD30 showed a minor positive correlation. The PRIME notation is considered universally applicable to antibodies, and notations of both FCM and IHC show great potential for big data.

P1, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting

P1, N=37, Completed, Washington University School of Medicine | Active, not recruiting --> Completed

P1, N=27, Recruiting, Fox Chase Cancer Center | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Dec 2021 --> Dec 2022

Intriguingly, CD30-negative population behaved as chemo-resistant cells in clinical course, however alectinib, a second-generation ALK-inhibitor, eradicated both populations inducing first complete remission...The cause of distinct ALK staining levels in immunohistochemistry was revealed depending on the distinct expression level of NPM-ALK mRNA transcripts. Finally, since both populations were sensitive to ALK-inhibitor, early administration of ALK-inhibitor might be the reasonable option for SC-ALCL.

In the ECHELON-2 phase 3 clinical trial, BV, cyclophosphamide, doxorubicin, and prednisone (A+CHP) showed efficacy in patients with peripheral T‑cell lymphoma (PTCL) across a range of CD30 expression levels, including the lowest eligible level of 10% by immunohistochemistry when compared with patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ( Advani 2019) . Medians for time‑to‑event analyses (e.g., median PFS) will be presented and two-sided 95% confidence intervals will be calculated using the log-log transformation method. Enrollment is planned for 15 US sites and 32 sites across the Czech Republic, France, Italy, and the UK.

This study demonstrates that priming with oral azacitidine (CC486) in combination with CHOP as initial therapy is safe, effective, and produces sustained remission in PTCL-TFH subtype. Epigenetic priming with azacitidine appears to inhibit the proliferation of TFH lymphoma cells, providing potential synergistic mechanism of action with chemotherapy. This active combination will be further evaluated in the upcoming ALLIANCE/ US Intergroup randomized study A051902, comparing oral azacitidine-CHO(E)P vs duvelisib-CHO(E)P against CHO(E)P in CD30 negative PTCL.

No abstract available

Survival analysis demonstrated that CD30-positive cases had a higher five-year overall survival rate (75%) than CD30-negative cases (32.3%), although a statistically significant result was not achieved (p = 0.19). Only a minor subset of oral and oropharyngeal DLBCL NOS express CD30 and these patients seems to have a higher survival rate.

Conversely, results observed above were absent in patients with low second-line IPI or patients older than 60 years or CD30-positive patients. Overall, the combination of chidamide and ChT may be an effective treatment strategy for R/R PTCL.

P1, N=37, Active, not recruiting, Washington University School of Medicine | Trial completion date: Jun 2021 --> Dec 2021

Ultimately, the CD30-based BV not only targets CD30 tumor cell but also CD30 DLBCL cells in the presence of CD30 EVs. Our study thus provides a feasible explanation for the clinical impact of BV in CD30 DLBCL and warrants confirming studies in animal models.

P1, N=18, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Sep 2036 --> Jan 2037 | Trial primary completion date: Sep 2021 --> Jan 2022